[Skip to Content]
[Skip to Content Landing]
Citations 0
March 3, 1999

Hormone Replacement Therapy for Secondary Prevention of Coronary Heart Disease

Author Affiliations

Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor

JAMA. 1999;281(9):794-797. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-9-jbk0303

To the Editor: The HERS report failed to show any effect of continuous combined conjugated equine estrogens and medroxyprogesterone acetate on coronary events.1 The null result is unexpected considering the strong observational evidence (discussed in the article) supporting a cardioprotective effect of HRT and the significant improvement in the lipid profile in the HRT group. Improvements in lipid profile have been shown to be associated with a decrease in cardiovascular events of approximately 46% for women in the Cholesterol and Recurrent Events Trial.2

First Page Preview View Large
First page PDF preview
First page PDF preview